SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit in New York on Thursday, February 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be ...

SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of common stock at a public offering price of $50.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,650,000 additional shares of common stock at the public offering price per share, less underwriting discounts and commissi ...

Core Viewpoint - Vaxcyte, Inc. has announced a public offering of common stock, aiming to raise $550 million through the sale of 11 million shares at a price of $50.00 per share, with an option for underwriters to purchase an additional 1.65 million shares [1][2]. Group 1: Offering Details - The public offering is expected to close on February 2, 2026, pending customary closing conditions [2]. - The offering is managed by several financial institutions, including BofA Securities, Jefferies, and Guggenheim Securities, among others [2]. Group 2: Company Overview - Vaxcyte is focused on developing high-fidelity vaccines to combat bacterial diseases, with notable candidates including VAX-31 and VAX-24, which are designed to prevent invasive pneumococcal disease [5][6]. - The company utilizes a proprietary cell-free protein synthesis platform, XpressCF®, to enhance the development of complex vaccines [6]. Group 3: Pipeline and Innovation - Vaxcyte's pipeline includes VAX-A1, aimed at preventing Group A Strep infections, and VAX-GI, designed to prevent Shigella [6]. - The company is innovating vaccine production methods to improve immunological benefits and expand coverage against various serotypes [5][6].

Vaxcyte Inc. (NASDAQ:PCVX) is one of the best US stocks to buy under $50. On January 23, Cantor Fitzgerald reaffirmed its Overweight rating on Vaxcyte Inc. (NASDAQ:PCVX), keeping a positive view as the company advances its vaccine pipeline on schedule. The firm expects topline results from the Phase 3 OPUS-1 trial in late 2026, with an adult BLA filing planned for 2027. Evercore ISI Rates Vaxcyte Inc. (PCVX) as an Overweight Following CDC Changes to Childhood Vaccination Recommendations It also noted pro ...

VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study in Adults Previously Vaccinated with Pneumococcal Vaccines (OPUS-3) in First Quarter of 2026 Company Expects to Report Topline Safety, Tolerability and Immunogenicity Data from Both OPUS-2 and OPUS-3 Phase 3 Studies in First Half of 2027, Supporting Planned BLA Submission VAX-31 Adult Phase 3 Noninferiority Tr ...

Company Overview - Vaxcyte is a clinical-stage biotechnology company focused on developing next-generation protein vaccines to meet unmet medical needs in bacterial infectious disease prevention [2] - The company's pipeline includes vaccines such as VAX-24 for pneumococcal disease, VAX-XP for emerging strains, VAX-A1 for Group A Strep, and VAX-PG for periodontitis [1][2] - Vaxcyte employs advanced conjugation and protein engineering technologies to enhance vaccine coverage and combat antibiotic resistance [2] Recent Insider Activity - Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte, sold 9,743 shares in an open-market transaction valued at approximately $454,891, reducing his direct ownership by 28.9% [4][5] - Following this sale, Dhaliwal's stake decreased from 33,671 shares to 23,928 shares, with no remaining indirect exposure [3][4] Stock Performance - Vaxcyte's stock price has declined by 44.2% over the past year, contrasting with an 18.4% return from the S&P 500 index during the same period [5] - The company's shares experienced a significant drop in late March and early April, followed by a modest recovery, which raises concerns about the sustainability of this momentum [6] Financial Performance - Vaxcyte does not have any approved products on the market, resulting in no revenue generation [6] - The company reported a loss of $520.1 million during the first nine months of 2025 [6] Future Outlook - Monitoring the approval process for Vaxcyte's vaccines will be crucial for assessing the company's future success [7] - Insider transactions, such as those by Dhaliwal, may provide insights into the confidence of company leadership regarding product approvals [7]

Core Insights - Vaxcyte remains a top pick for Mizuho Securities as it approaches 2026, indicating strong confidence in the company's future performance [1] Company Summary - Vaxcyte is recognized for its innovative approach in the vaccine sector, which positions it favorably among investors [1] - The company is expected to continue its growth trajectory, supported by its robust pipeline and strategic initiatives [1] Industry Summary - The vaccine industry is experiencing significant advancements, with companies like Vaxcyte leading the way in innovation and development [1] - Mizuho Securities' endorsement reflects a positive outlook for the vaccine market, suggesting potential for substantial returns in the coming years [1]

Core Viewpoint - Vaxcyte Inc. (NASDAQ:PCVX) is identified as a promising mid-cap healthcare stock with significant upside potential, supported by positive analyst ratings and upcoming clinical trials [1][4]. Group 1: Analyst Ratings and Price Targets - BTIG analyst Thomas Shrader has reiterated a Buy rating for Vaxcyte Inc. with a target price of $85, indicating an upside of over 83% from current levels [1]. - Consensus ratings show all 7 analysts have assigned Buy ratings, with a median 1-year price target of $100.80 per share, representing a potential upside of 117.2% [4]. Group 2: Clinical Trials and Product Development - Positive results from Phase 2 trials for the VAX-31 vaccine are expected to support the critical Phase 3 trials, which have a robust design and stringent success criteria [2]. - The target market for VAX-31 includes individuals aged 50 to 65, suggesting strong potential for market adoption [3]. - Vaxcyte Inc. focuses on developing next-generation vaccines using innovative synthetic methods and advanced chemistry to enhance immunological benefits [5].

Core Insights - The pneumococcal vaccine market has been historically dominated by large companies utilizing conventional conjugate chemistry methods, which are effective but face limitations due to a phenomenon known as "carrier suppression" [1] Group 1: Market Dynamics - The traditional conjugate chemistries in the pneumococcal vaccine market have a biological ceiling that restricts their effectiveness [1] Group 2: Investment Perspective - There is a strong inclination towards high-growth companies in sectors that are expected to experience exponential expansion, with a focus on disruptive technologies and innovative enterprises [1]

Core Insights - The pneumococcal vaccine market has been historically dominated by large companies utilizing conventional conjugate chemistry methods, which are effective but face limitations due to a phenomenon known as "carrier suppression" [1] Group 1: Market Dynamics - The traditional conjugate chemistries in the pneumococcal vaccine market have reached a biological ceiling, indicating a need for innovation to overcome these limitations [1] Group 2: Investment Perspective - There is a strong inclination towards high-growth companies in sectors that are expected to experience exponential expansion, highlighting the potential for disruptive technologies and forward-thinking enterprises [1]